Late-stage investigational treatments for schizophrenia have been able to target not only the positive symptoms of schizophrenia, but also the negative and cognitive symptoms as well. This could allow health care professionals (HCPs) the ability to individualize treatment plans to meet the specific needs of their patients in the near future. HCPs, however, may be unaware of the effects of these novel therapies and the varying domains of schizophrenia that the treatments can influence.
In the third installment of this three-part Journal Club series, Targeting Domains of Schizophrenia with Individualized Therapy, expert faculty will present the latest information on targeted treatments for schizophrenia phenotypes to help HCPs make the best choices in individualized therapies for their patients.
Assess current and emerging data for therapies for the treatment of varying schizophrenia phenotypes
Supported in whole or in part by an educational grant from Sunovion and Otsuka.
Psychiatrists, nurse practitioners (NPs), physician associates (PAs), psychiatric nurses, and pharmacists
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Kantrowitz reports the following financial relationships:
Advisory Board: Jazz Pharmaceuticals, Inc.; Karuna Therapeutics; Leal Therapeutics; MedinCell; and Merck & Co., Inc.
Consultant: AlphaSights; Antheum; Clarivate; Clearview; ECRI Institute; Evoke Pharma; ExpertConnect; Evoke Pharma; First Thought; GKA; GlobalData; Guidepoint Global, LLC.; Health Monitor; Jefferies; Market Plus; MEDACorp, Inc.; Otsuka America Pharmaceutical, Inc.; Putnam; Reckner; Slingshot Biosciences, Inc.; SmartAnalyst; SR One Capital Management; Techspert.io Ltd; Third Bridge; Trinity; VoxNeuro Inc.; and Wedbush
Grants and Research Support: Supported by the NIMH, Boehringer Ingelheim; Cerevance; Click Therapeutics, Inc., Corcept; Neurocrine Biosciences, Inc.; Roche; Sunovion Pharmaceuticals Inc.; and Pharmaceutical Holdings Co., Ltd.
Stock Shareholder (directly purchased): GSK
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).